Julie N. Graff, MD | Authors

MSC

11 STUTZ CT

Articles

The Relationship Between Checkpoint Inhibitors and the Gut Microbiome and Its Application in Prostate Cancer

March 19, 2020

This review article discusses the concepts of a tumor microenvironment and a gut microbiome and their effects on responses to checkpoint inhibitors (CPIs). It also reviews recent research investigating these 3 topics, and how it can be applied to using CPIs in prostate cancer.

Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer

December 17, 2018

This article reviews the mechanism of action between GnRH agonists and antagonists and the studies that led to the approval of degarelix, as well as its potential risks and benefits, particularly when it comes to cardiovascular health.

Prostate Cancer Outlook for 2017: The Search for Actionable Targets Continues

December 14, 2016

Six therapies have demonstrated improved survival in metastatic castration-resistant prostate cancer, yet there is insufficient data regarding combination and sequencing of these agents, and predicting response or resistance to them. Prostate cancer patients, researchers, and clinicians alike await the results of key phase III studies in 2017 that could further impact how prostate cancer is managed.

Treatment of Nonmetastatic Castration-Resistant Prostate Cancer

April 16, 2016

Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.

Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer

June 15, 2015

Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223 and review the available data regarding the cost of denosumab compared with that of zoledronic acid.

Targeted Therapy in Prostate Cancer: Is There Hope Beyond the Androgen Receptor?

July 15, 2013

We need to understand each patient’s cancer and its microenvironment well enough to develop targeted treatments that will kill the tumor the first time-for if we let it escape, 70 years of prostate cancer research teaches us that our job will only get harder.